Ilan Wapinski

[Ilan Wapinski @IWapinski]

@eitanhersh By next fall, we should have concrete data to measure this

[PathAI @Path_AI]

We are thrilled to announce that we have received both FDA 510(k) clearance and CE Mark for AISight Dx, a digital pathology platform for the purpose of primary diagnosis in clinical settings. More here: https://t.co/Byp0J2gTi6

[PathAI @Path_AI]

We will be sharing 6 posters during AACR 2022, 3 of which were developed in collaboration with pharmaceutical partners. Read more here: https://t.co/gD8lx0Zmlg

[PathAI @Path_AI]

PathAI and @GSK are announcing a strategic multi-year partnership to accelerate scientific research and drug development programs in oncology and NASH by leveraging PathAI’s technologies, including the use of PathAI’s AIM-NASH tool https://t.co/Oo0ZmFdoRe

[Alasdair Munro @apsmunro]

In case there was any doubt left as to the effect the past 2 years have had on the mental health of our children and young people

*THIS* is the health emergency they are facing

Where’s the “nightingale wards” response for children’s mental health?

https://t.co/gq82dmAAjO

[Ilan Wapinski @IWapinski]

It’s going to be fascinating to see the zip code break down for where the free rapid test orders come from:
https://t.co/sGIPexF19F

[Michael Baym @baym]

There’s no doubt N95/KN95/KF94/FFP2 is better than surgical is better than cloth but the numbers in this graphic are classic data bullshit

[Nate Silver @NateSilver538]

@ClaraJeffery @DennisDoubleday @JamesSurowiecki I think COVID polices such as school closures have been extremely damaging to children and I think it would be unethical if I didn't express that and I don't really care if it pisses people off.

[Ilan Wapinski @IWapinski]

@TommyVitolo @TownofBrookline What types of platforms would you say they use? I’m only familiar with sending letters through currier pigeons…

[PathAI @Path_AI]

PathAI is excited to present our new research in AI-based UC models at #IBDInnovate hosted by @CrohnsColitisFn. If you are attending the conference, catch our presentation tomorrow at 3:45 ET!

[PathAI @Path_AI]

New data on AI in NASH demonstrate statistically significant treatment effect relative to placebo in addition to dose-dependent response in Phase 2 clinical tria Learn more about our AASLD poster in collaboration with Novo Nordisk https://t.co/U0b37UecX1

[PathAI @Path_AI]

We are excited to announce a new partnership with Roche! This partnership brings together PathAI’s market-leading artificial intelligence-powered technology and Roche’s assay development and digital pathology capabilities. https://t.co/FTY7miOsZ1

[PathAI @Path_AI]

PathAI is thrilled to announce our partnership with Summit Clinical Research! The collaboration aims to alleviate many key challenges facing NASH drug development progress by offering an integrated solution to NASH drug developers.
Read more here: https://t.co/ix1IHStv9K

[PathAI @Path_AI]

Join us at the World CDx Summit! PathAI’s Andy Beck will be discussing how AI-powered CDx development can unlock new opportunities in precision medicine programs.

Register Now! https://t.co/8FGRuSHZId

[Ilan Wapinski @IWapinski]

@amarotaylorw @VanAllenLab @celtics @NatureGenet @Lakers @KevinOConnorNBA @SheaSerrano @MagicJohnson @LakersReporter @DanaFarber @broadinstitute Some of us will applaud him. Good warning about his penchant for racking up AWS bills… lucky for him we have our own cluster here.

[PathAI @Path_AI]

PathAI is thrilled to announce our acquisition of Poplar Healthcare. Combining the companies’ complementary expertise provides PathAI with end-to-end capabilities to support the development and delivery of new and distinctive AI-driven products. https://t.co/4dfhuOvjdG #PathAI

[PathAI @Path_AI]

We are thrilled to welcome Dr. Eric Walk to the PathAI Team as Chief Medical Officer! Dr. Walk brings 20 years of experience in medical & scientific affairs, oncology drug development, and translational medicine. https://t.co/BU1TCZeMC3

[PathAI @Path_AI]

PathAI presented new data describing improved digital assessment of nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) at the Virtual International Liver Conference this week. Learn more about the different presentations here: https://t.co/8w8L8ojztn

[PathAI @Path_AI]

PathAI and Genentech will present data at ASCO 2021 that highlights the application of its ML-based pathologic response algorithm to clinical trials as an aid to pathologists. Learn more about the study here: https://t.co/HN8Dx5bMFB

[PathAI @Path_AI]

Today is a major milestone for PathAI as we announce $165M in Series C financing led by D1 Capital Partners and Kaiser Permanente. The new capital will drive growth with the expansion of our product suite and commercial footprint. https://t.co/ATqqxoLyJ3